Search

Your search keyword '"Ritchey, Julie"' showing total 547 results
Start Over Author "Ritchey, Julie"
547 results on '"Ritchey, Julie"'

2. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

Author

Frigault, Matthew J., Graham, Charlotte E., Berger, Trisha R., Ritchey, Julie, Horick, Nora K., El-Jawahri, Areej, Scarfò, Irene, Schmidts, Andrea, Haradhvala, Nicholas J., Wehrli, Marc, Lee, Won-Ho, Parker, Aiyana L., Wiggin, Hadley R., Bouffard, Amanda, Dey, Aonkon, Leick, Mark B., Katsis, Katelin, Elder, Eva L., Dolaher, Maria A., Cook, Daniella T., Chekmasova, Alena A., Huang, Lu, Nikiforow, Sarah, Daley, Heather, Ritz, Jerome, Armant, Myriam, Preffer, Fred, DiPersio, John F., Nardi, Valentina, Chen, Yi-Bin, Gallagher, Kathleen M. E., and Maus, Marcela V.

Published
2024
Full Text
View/download PDF

5. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells

Author

O’Neal, Julie, Ritchey, Julie K., Cooper, Matthew L., Niswonger, Jessica, Sofía González, L., Street, Emily, Rettig, Michael P., Gladney, Susan W., Gehrs, Leah, Abboud, Ramzi, Prior, Julie L., Haas, Gabriel J., Jayasinghe, Reyka G., Ding, Li, Ghobadi, Armin, Vij, Ravi, and DiPersio, John F.

Published
2022
Full Text
View/download PDF

10. Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc

Author

O'Neal, Julie, primary, Cooper, Matthew L., additional, Ritchey, Julie K., additional, Gladney, Susan, additional, Niswonger, Jessica, additional, Sofía González, L., additional, Street, Emily, additional, Haas, Gabriel J., additional, Carter, Alun, additional, Amayta, Parmeshwar N., additional, Gao, Feng, additional, Ha Lee, Byung, additional, Choi, Donghoon, additional, Berrien-Elliott, Melissa, additional, Zhou, Alice, additional, Fehniger, Todd A., additional, Rettig, Mike P., additional, and DiPersio, John F., additional

Published
2024
Full Text
View/download PDF

11. Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization

Author

Cancilla, Daniel, primary, Rettig, Michael P., additional, Karpova, Darja, additional, Thakellapalli, Haresh, additional, Singh, Megh, additional, Meyers, Marvin J., additional, Ruminski, Peter G., additional, Christ, Stephanie, additional, Chendamarai, Ezhilarasi, additional, Gao, Feng, additional, Gehrs, Leah, additional, Ritchey, Julie K., additional, Prinsen, Michael, additional, and DiPersio, John F., additional

Published
2024
Full Text
View/download PDF

12. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+lymphoid malignancies

Author

Frigault, Matthew J., Graham, Charlotte E., Berger, Trisha R., Ritchey, Julie, Horick, Nora K., El-Jawahri, Areej, Scarfò, Irene, Schmidts, Andrea, Haradhvala, Nicholas J., Wehrli, Marc, Lee, Won-Ho, Parker, Aiyana L., Wiggin, Hadley R., Bouffard, Amanda, Dey, Aonkon, Leick, Mark B., Katsis, Katelin, Elder, Eva L., Dolaher, Maria A., Cook, Daniella T., Chekmasova, Alena A., Huang, Lu, Nikiforow, Sarah, Daley, Heather, Ritz, Jerome, Armant, Myriam, Preffer, Fred, DiPersio, John F., Nardi, Valentina, Chen, Yi-Bin, Gallagher, Kathleen M. E., and Maus, Marcela V.

Abstract

•CAR-37 T cells expanded to >98% of T cells and led to complete responses but caused severe cytopenia associated with high levels of IL-18.•Depleting CAR-37 T cells using cetuximab to target the safety switch was unsuccessful in the setting of neutropenia.

Published
2024
Full Text
View/download PDF

15. Rational protein engineering to enhance MHC-independent T cell receptors

Author

Chang, Ju-Fang, primary, Landmann, Jack H., additional, Chang, Tien-Ching, additional, Tenzin, Yangdon, additional, Warrington, John M., additional, Selli, Mehmet Emrah, additional, Ritchey, Julie, additional, Hsu, Yu-Sung, additional, Slade, Michael, additional, Gupta, Deepesh Kumar, additional, DiPersio, John F., additional, and Singh, Nathan, additional

Published
2024
Full Text
View/download PDF

17. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.

Author

Eissenberg, Linda G., Ritchey, Julie K., Rettig, Michael P., Patel, Dilan A., Vij, Kiran, Gao, Feng, Smith, Victoria, Han, Tae H., and DiPersio, John F.

Subjects
*T cells, *ACUTE myeloid leukemia, *IMMUNOLOGIC memory, *TUMOR antigens, *CD3 antigen, *BLOOD cells
Abstract

Off-the-shelf immunotherapeutics that suppress tumor growth and provide durable protection against relapse could enhance cancer treatment. We report preclinical studies on a CD33 x CD3 bivalent bispecific diabody, AMV564, that not only suppresses tumor growth, but also facilitates memory responses in a mouse model of acute myelogenous leukemia (AML). Mechanistically, a single 5-day treatment with AMV564 seems to reduce tumor burden by redirection of T cells, providing a time window for allogeneic or other T cells that innately recognize tumor antigens to become activated and proliferate. When the concentration of bispecific becomes negligible, the effector: target ratio has also shifted, and these activated T cells mediate long-term tumor control. To test the efficacy of AMV564 in vivo, we generated a CD33+ MOLM13CG bioluminescent human cell line and optimized conditions needed to control these cells for 62 days in vivo in NSG mice. Of note, not only did MOLM13CG become undetectable by bioluminescence imaging in response to infusion of human T cells plus AMV564, but also NSG mice that had cleared the tumor also resisted rechallenge with MOLM13CG in spite of no additional AMV564 treatment. In these mice, we identified effector and effector memory human CD4+ and CD8+ T cells in the peripheral blood immediately prior to rechallenge that expanded significantly during the subsequent 18 days. In addition to the anti-tumor effects of AMV564 on the clearance of MOLM13CG cells in vivo, similar effects were seen when primary CD33+ human AML cells were engrafted in NSG mice even when the human T cells made up only 2% of the peripheral blood cells and AML cells made up 98%. These studies suggest that AMV564 is a novel and effective bispecific diabody for the targeting of CD33+ AML that may provide long-term survival advantages in the clinic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial

Author

Goldsmith, Scott R, primary, Covut, Fahrettin, additional, Fiala, Mark, additional, Xiang, Zhifu, additional, Iqbal, Zahid, additional, Moore, Nathan, additional, Bradtke, Elizabeth, additional, Christen, Brandon, additional, Rettig, Michael P, additional, Christ, Stephanie, additional, Gehrs, Leah, additional, Street, Emily, additional, Wallace, Nicholas, additional, Ritchey, Julie, additional, Gao, Feng, additional, Pachter, Jonathan, additional, Parikh, Bijal, additional, Dubberke, Erik R, additional, and DiPersio, John F, additional

Published
2023
Full Text
View/download PDF

20. Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models

Author

Abboud, Ramzi, primary, Kim, Sena, additional, Staser, Karl, additional, Jayasinghe, Reyka G., additional, Lim, Sora, additional, Amatya, Parmeshwar, additional, Frye, C. Corbin, additional, Kopecky, Benjamin, additional, Ritchey, Julie, additional, Gao, Feng, additional, Lavine, Kory, additional, Kreisel, Daniel, additional, DiPersio, John F., additional, and Choi, Jaebok, additional

Published
2023
Full Text
View/download PDF

23. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells

Author

Karpova, Darja, Rettig, Michael P., Ritchey, Julie, Cancilla, Daniel, Gehrs, Stephanie ChrisLeah, Chendamarai, Ezhilarasi, Evbuomwan, Moses O., Zhang, Matthew HolJingzhu, Abou-Ezzi, Grazia, Celik, Hamza, Wiercinska, Eliza, Yang, Wei, Gao, Feng, Eissenberg, Linda G., Heier, Richard F., Arnet, Stacy D., Meyers, Marvin J., Prinsen, Michael J., Griggs, David W., Trumpp, Andreas, Ruminski, Peter G., Morrow, Dwight M., Bonig, Halvard B., Link, Daniel C., and DiPersio, John F.

Subjects
R and D Systems, Hematopoietic stem cells, Combination drug therapy, Software industry, Hematopoietic stem cell transplantation, Integrins, Plerixafor, Stem cells, Antigens, Surgery, Stem cell transplantation, Granulocyte colony-stimulating factor, Health care industry, Washington University. School of Medicine
Abstract

Mobilized peripheral blood has become the primary source of hematopoietic stem and progenitor cells (HSPCs) for stem cell transplantation, with a 5-day course of granulocyte colony-stimulating factor (G-CSF) as the most common regimen used for HSPC mobilization. The CXCR4 inhibitor plerixafor is a more rapid mobilizer, yet not potent enough when used as a single agent, thus emphasizing the need for faster acting agents with more predictable mobilization responses and fewer side effects. We sought to improve hematopoietic stem cell transplantation by developing a new mobilization strategy in mice through combined targeting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin. Rapid and synergistic mobilization of HSPCs along with an enhanced recruitment of true HSCs was achieved when a CXCR2 agonist was coadministered in conjunction with a VLA4 inhibitor. Mechanistic studies revealed involvement of CXCR2 expressed on BM stroma in addition to stimulation of the receptor on granulocytes in the regulation of HSPC localization and egress. Given the rapid kinetics and potency of HSPC mobilization achieved by the VLA4 inhibitor and CXCR2 agonist combination in mice compared with currently approved HSPC mobilization methods, the combination represents an exciting potential strategy for clinical development in the future., Introduction In postnatal mammals, the vast majority of hematopoietic stem and progenitor cells (HSPCs) reside in the protective environment of the bone marrow (BM) (1, 2). Accordingly, only very few [...]

Published
2019
Full Text
View/download PDF

24. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation

Author

Persaud, Stephen P., Ritchey, Julie K., Kim, Sena, Lim, Sora, Ruminski, Peter G., Cooper, Matthew L., Rettig, Michael P., Choi, Jaebok, and DiPersio, John F.

Subjects
Antibody-drug conjugates -- Patient outcomes, Blood diseases -- Care and treatment, Enzyme inhibitors -- Patient outcomes, Hematopoietic stem cells -- Transplantation, Health care industry
Abstract

Despite the curative potential of hematopoietic stem cell transplantation (HSCT), conditioning-associated toxicities preclude broader clinical application. Antibody-drug conjugates (ADCs) provide an attractive approach to HSCT conditioning that minimizes toxicity while retaining efficacy. Initial studies of ADC conditioning have largely focused on syngeneic HSCT. However, to treat acute leukemias or induce tolerance for solid organ transplantation, this approach must be expanded to allogeneic HSCT (allo-HSCT). Using murine allo-HSCT models, we show that pharmacologic Janus kinase 1/2 (JAK1/2) inhibition combined with CD45- or cKit-targeted ADCs enables robust multilineage alloengraftment. Strikingly, myeloid lineage donor chimerism exceeding 99% was achievable in fully MHC-mismatched HSCT using this approach. Mechanistic studies using the JAK1/2 inhibitor baricitinib revealed marked impairment of T and NK cell survival, proliferation, and effector function. NK cells were exquisitely sensitive to JAK1/2 inhibition due to interference with IL-15 signaling. Unlike irradiated mice, ADC-conditioned mice did not develop pathogenic graft-versus-host alloreactivity when challenged with mismatched T cells. Finally, the combination of ADCs and baricitinib balanced graft-versus- host disease and graft-versus-leukemia responses in delayed donor lymphocyte infusion models. Our allo-HSCT conditioning strategy exemplifies the promise of immunotherapy to improve the safety of HSCT for treating hematologic diseases., Introduction Hematopoietic stem cell transplantation (HSCT) has therapeutic potential for hematologic malignancies, autoimmunity, immunodeficiency, chronic infection, or tolerance induction for solid organ transplantation (SOT) (1-3). However, two formidable barriers must [...]

Published
2021
Full Text
View/download PDF

25. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells

Author

Karpova, Darja, Ritchey, Julie K., Holt, Matthew S., Abou-Ezzi, Grazia, Monlish, Darlene, Batoon, Lena, Millard, Susan, Spohn, Gabriele, Wiercinska, Eliza, Chendamarai, Ezhil, Yang, Wei, Christ, Stephanie, Gehrs, Leah, Schuettpelz, Laura G., Dembowsky, Klaus, Pettit, Allison R., Rettig, Michael P., Bonig, Halvard, and DiPersio, John F.

Published
2017
Full Text
View/download PDF

27. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Author

Cooper, Matthew L, Choi, Jaebok, Staser, Karl, Ritchey, Julie K, Devenport, Jessica M, Eckardt, Kayla, Rettig, Michael P, Wang, Bing, Eissenberg, Linda G, Ghobadi, Armin, Gehrs, Leah N, Prior, Julie L, Achilefu, Samuel, Miller, Christopher A, Fronick, Catrina C, O’Neal, Julie, Gao, Feng, Weinstock, David M, Gutierrez, Alejandro, Fulton, Robert S, and DiPersio, John F

Published
2018
Full Text
View/download PDF

28. Supplementary Table S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Author

Buatois, Vanessa, primary, Johnson, Zoë, primary, Salgado-Pires, Susana, primary, Papaioannou, Anne, primary, Hatterer, Eric, primary, Chauchet, Xavier, primary, Richard, Françoise, primary, Barba, Leticia, primary, Daubeuf, Bruno, primary, Cons, Laura, primary, Broyer, Lucile, primary, D'Asaro, Matilde, primary, Matthes, Thomas, primary, LeGallou, Simon, primary, Fest, Thierry, primary, Tarte, Karin, primary, Clarke Hinojosa, Robert K., primary, Genescà Ferrer, Eulàlia, primary, Ribera, José María, primary, Dey, Aditi, primary, Bailey, Katharine, primary, Fielding, Adele K., primary, Eissenberg, Linda, primary, Ritchey, Julie, primary, Rettig, Michael, primary, DiPersio, John F., primary, Kosco-Vilbois, Marie H., primary, Masternak, Krzysztof, primary, Fischer, Nicolas, primary, Shang, Limin, primary, and Ferlin, Walter G., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Materials and Methods from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Author

Buatois, Vanessa, primary, Johnson, Zoë, primary, Salgado-Pires, Susana, primary, Papaioannou, Anne, primary, Hatterer, Eric, primary, Chauchet, Xavier, primary, Richard, Françoise, primary, Barba, Leticia, primary, Daubeuf, Bruno, primary, Cons, Laura, primary, Broyer, Lucile, primary, D'Asaro, Matilde, primary, Matthes, Thomas, primary, LeGallou, Simon, primary, Fest, Thierry, primary, Tarte, Karin, primary, Clarke Hinojosa, Robert K., primary, Genescà Ferrer, Eulàlia, primary, Ribera, José María, primary, Dey, Aditi, primary, Bailey, Katharine, primary, Fielding, Adele K., primary, Eissenberg, Linda, primary, Ritchey, Julie, primary, Rettig, Michael, primary, DiPersio, John F., primary, Kosco-Vilbois, Marie H., primary, Masternak, Krzysztof, primary, Fischer, Nicolas, primary, Shang, Limin, primary, and Ferlin, Walter G., primary

Published
2023
Full Text
View/download PDF

30. Video 1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Author

Buatois, Vanessa, primary, Johnson, Zoë, primary, Salgado-Pires, Susana, primary, Papaioannou, Anne, primary, Hatterer, Eric, primary, Chauchet, Xavier, primary, Richard, Françoise, primary, Barba, Leticia, primary, Daubeuf, Bruno, primary, Cons, Laura, primary, Broyer, Lucile, primary, D'Asaro, Matilde, primary, Matthes, Thomas, primary, LeGallou, Simon, primary, Fest, Thierry, primary, Tarte, Karin, primary, Clarke Hinojosa, Robert K., primary, Genescà Ferrer, Eulàlia, primary, Ribera, José María, primary, Dey, Aditi, primary, Bailey, Katharine, primary, Fielding, Adele K., primary, Eissenberg, Linda, primary, Ritchey, Julie, primary, Rettig, Michael, primary, DiPersio, John F., primary, Kosco-Vilbois, Marie H., primary, Masternak, Krzysztof, primary, Fischer, Nicolas, primary, Shang, Limin, primary, and Ferlin, Walter G., primary

Published
2023
Full Text
View/download PDF

31. Data from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Author

Buatois, Vanessa, primary, Johnson, Zoë, primary, Salgado-Pires, Susana, primary, Papaioannou, Anne, primary, Hatterer, Eric, primary, Chauchet, Xavier, primary, Richard, Françoise, primary, Barba, Leticia, primary, Daubeuf, Bruno, primary, Cons, Laura, primary, Broyer, Lucile, primary, D'Asaro, Matilde, primary, Matthes, Thomas, primary, LeGallou, Simon, primary, Fest, Thierry, primary, Tarte, Karin, primary, Clarke Hinojosa, Robert K., primary, Genescà Ferrer, Eulàlia, primary, Ribera, José María, primary, Dey, Aditi, primary, Bailey, Katharine, primary, Fielding, Adele K., primary, Eissenberg, Linda, primary, Ritchey, Julie, primary, Rettig, Michael, primary, DiPersio, John F., primary, Kosco-Vilbois, Marie H., primary, Masternak, Krzysztof, primary, Fischer, Nicolas, primary, Shang, Limin, primary, and Ferlin, Walter G., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure S2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Author

Buatois, Vanessa, primary, Johnson, Zoë, primary, Salgado-Pires, Susana, primary, Papaioannou, Anne, primary, Hatterer, Eric, primary, Chauchet, Xavier, primary, Richard, Françoise, primary, Barba, Leticia, primary, Daubeuf, Bruno, primary, Cons, Laura, primary, Broyer, Lucile, primary, D'Asaro, Matilde, primary, Matthes, Thomas, primary, LeGallou, Simon, primary, Fest, Thierry, primary, Tarte, Karin, primary, Clarke Hinojosa, Robert K., primary, Genescà Ferrer, Eulàlia, primary, Ribera, José María, primary, Dey, Aditi, primary, Bailey, Katharine, primary, Fielding, Adele K., primary, Eissenberg, Linda, primary, Ritchey, Julie, primary, Rettig, Michael, primary, DiPersio, John F., primary, Kosco-Vilbois, Marie H., primary, Masternak, Krzysztof, primary, Fischer, Nicolas, primary, Shang, Limin, primary, and Ferlin, Walter G., primary

Published
2023
Full Text
View/download PDF

33. Video 2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Author

Buatois, Vanessa, primary, Johnson, Zoë, primary, Salgado-Pires, Susana, primary, Papaioannou, Anne, primary, Hatterer, Eric, primary, Chauchet, Xavier, primary, Richard, Françoise, primary, Barba, Leticia, primary, Daubeuf, Bruno, primary, Cons, Laura, primary, Broyer, Lucile, primary, D'Asaro, Matilde, primary, Matthes, Thomas, primary, LeGallou, Simon, primary, Fest, Thierry, primary, Tarte, Karin, primary, Clarke Hinojosa, Robert K., primary, Genescà Ferrer, Eulàlia, primary, Ribera, José María, primary, Dey, Aditi, primary, Bailey, Katharine, primary, Fielding, Adele K., primary, Eissenberg, Linda, primary, Ritchey, Julie, primary, Rettig, Michael, primary, DiPersio, John F., primary, Kosco-Vilbois, Marie H., primary, Masternak, Krzysztof, primary, Fischer, Nicolas, primary, Shang, Limin, primary, and Ferlin, Walter G., primary

Published
2023
Full Text
View/download PDF

34. Suppl Figure 6 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

35. Suppl Figure 2 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

36. Suppl Figure 3 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

38. Suppl Figure 4 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

39. Suppl Figure 5 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

40. Suppl Figure 1 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Author

Fontana, Francesca, primary, Scott, Michael J., primary, Allen, John S., primary, Yang, Xiaoxia, primary, Cui, Grace, primary, Pan, Dipanjan, primary, Yanaba, Noriko, primary, Fiala, Mark A., primary, O'Neal, Julie, primary, Schmieder-Atteberry, Anne H., primary, Ritchey, Julie, primary, Rettig, Michael, primary, Simons, Kathleen, primary, Fletcher, Steven, primary, Vij, Ravi, primary, DiPersio, John F., primary, and Lanza, Gregory M., primary

Published
2023
Full Text
View/download PDF

44. S100A9 up-regulated by IFNGR signaling blockade functions as a novel GvHD suppressor without compromising GvL in mice

Author

Kim, Sena, primary, Lim, Sora, additional, Kim, Boram, additional, Ritchey, Julie, additional, Vij, Kiran, additional, Prior, Julie, additional, Marsala, Lynne, additional, Stoner, Alyssa, additional, Gao, Feng, additional, Achilefu, Samuel, additional, Cooper, Matthew L, additional, DiPersio, John F., additional, and Choi, Jaebok, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results